ArticleFrontiers in oncology2025
Multimodal integration of [
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Explainable Machine Learning-Based Overall Survival Classification in Prostate Adenocarcinoma Using Integrated Clinical and Transcriptomic Features.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate cancer is one of the most prevalent malignant tumors of the male genitourinary system. The occurrence of metastasis significantly influences treatment strategies and prognosis. However, current risk assessments for metastatic disease primarily rely on single imaging or pathological indicators, which are often limited by suboptimal accuracy and considerable individual variability. Objective: This study aimed to develop a high-performance predictive model for prostate cancer metastasis by integrating semiquantitative parameters from [ Methods: We retrospectively analyzed data from prostate cancer patients, includingPSMA PET/CT-derived features (SUVmax, SUVmean, PSMA-TVp, TL-PSMAp) and clinical-pathological variables (age, tPSA, Gleason score). Five machine learningalgorithms-Logistic Regression, Support Vector Machine, Random Forest, Naive Bayes, and XGBoost-were evaluated for metastasis prediction performance. Model performance was assessed using accuracy, sensitivity, precision, and area under the ROC curve (AUC). Shapley additive explanations (SHAP) were applied to interpret the most effective model. Results: Among the five algorithms, the XGBoost model achieved an accuracy of 90.32%, sensitivity of 90.0%, specificity of 94.74%, and an AUC of 0.8977. SHAP analysis identified PSMA-TVp, TL-PSMAp as the most important predictors, followed by SUVmax, tPSA, and Gleason score. These findings highlight the key role of PSMA-derived tumor burden in metastasis prediction. Force plots further revealed the individual-level contributions of features, supporting the model's clinical interpretability. Conclusion: The XGBoost-based multimodal model integrating PET/CT semiquantitative parameters with clinicopathological data demonstrated excellent accuracy and interpretability in predicting prostate cancer metastasis. This approach has strong potential for clinical application and may provide a valuable tool for personalized treatment decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.